Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches
The presence of acquired mutations within the JAK2, CALR, and MPL genes in the majority of patients with myeloproliferative neoplasms (MPN) affords the opportunity to utilise these mutations as markers of minimal residual disease (MRD). Reduction of the mutated allele burden has been reported in res...
Main Authors: | Karl Haslam, Stephen E. Langabeer |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2016/7241591 |
Similar Items
-
Monitoring residual disease in the Ph-negative myeloproliferative neoplasms post-allogeneic stem cell transplantation: more mutations and more methodologies.
by: Stephen eLangabeer, et al.
Published: (2014-08-01) -
Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia
by: Stephen E Langabeer, et al.
Published: (2017-04-01) -
CALR mutation profile in Irish patients with myeloproliferative neoplasms
by: Karl Haslam, et al.
Published: (2016-09-01) -
Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia
by: Stephen E. Langabeer
Published: (2020-01-01) -
Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia
by: Karl Haslam, et al.
Published: (2012-01-01)